Sangamo gains on Phase I/II readout for hemophilia A gene therapy

Interim Phase I/II data for Sangamo’s hemophilia A gene therapy Tuesday helped shares of the company complete a round-trip from its 31% tumble on a February readout for its mucopolysaccharidosis therapies. Sangamo Therapeutics Inc. (NASDAQ:SGMO) added $2.76 (29%) to $12.29 on Tuesday.

Sangamo and partner Pfizer Inc. (NYSE:PFE) said that SB-525 led to dose-dependent increases in Factor VIII levels in eight severe hemophilia A patients across four dose cohorts in the open-label Phase I/II Alta trial. Additionally, the two patients who received the fourth dose level of SB-525, 3x10¹³ vector genomes per kg (vg/kg) achieved Factor VIII activity levels at week 6 following infusion of 140% and 94% of normal as measured by the one-stage clotting assay and of 95% and 65% of normal as measured by chromogenic assay...